Join to View Full Profile
200 Hawkins DrDepartment of Internal MedicineIowa City, IA 52242
Phone+1 319-356-4422
Fax+1 319-353-8383
Dr. Farooq is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Umar Farooq is an oncologist based in Iowa City, IA. He completed his fellowship in Hematology and Medical Oncology at the University of Connecticut in 2013 and holds a medical degree from Allama Iqbal Medical College. His residency in Internal Medicine was completed at UPMC Medical Education (Harrisburg). Dr. Farooq has authored several publications in reputable journals, including studies on diffuse large B-cell lymphoma in the American Journal of Hematology and Blood Advances. He is also involved in clinical trials, including research on CMP-001 for relapsed and refractory lymphoma and treatments for first-relapse or primary refractory diffuse large B-cell lymphoma.
Education & Training
University of ConnecticutFellowship, Hematology and Medical Oncology, 2010 - 2013
UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 2007 - 2010
Allama Iqbal Medical CollegeClass of 2003
Certifications & Licensure
IA State Medical License 2013 - 2026
CA State Medical License 2013 - 2025
PA State Medical License 2007 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2016 May 20
- CMP-001 for Relapsed and Refractory Lymphoma Start of enrollment: 2020 Jan 31
Publications & Presentations
PubMed
- Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.Suheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, Matthew J Rees, Juan Pablo Alderuccio
American Journal of Hematology. 2025-09-03 - New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell Lymphoma.Uri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, Soyoung Kim, Amy Moskop
Blood Advances. 2025-08-14 - Autologous Transplant or CAR-T as Consolidation Options in MYC Rearranged Large B-Cell Lymphoma Patients in Remission After Salvage Treatments.Fateeha Furqan, Kwang W Ahn, Manmeet Kaur, Jinalben Patel, Stephen Ansell
American Journal of Hematology. 2025-07-01
Abstracts/Posters
- Age and Time to Progression Predict Overall Survival (OS) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Who Progress Following Frontline Immunochemotherapy (IC)Umar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell LymphomaUmar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell LymphomaUmar Farooq, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
